Can-Fite BioPharma
About Science Pipeline Investor Information Contact Us

Investor Information

Investor Information

Investor Information

Company Information

Can-Fite BioPharma Ltd. (NYSE American: CANF)

Can-Fite BioPharma Ltd. is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of inflammatory, cancer, and metabolic diseases. The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its endpoints in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in approximately 2,000 patients in clinical studies to date.

Stock Information

Last Change Volume

Can-Fite's ADRs trade in the USA under the ticker CANF and the ordinary shares trade on the Tel-Aviv Stock Exchange under the ticker CFBI.

More on CFBI »

Investor Relations

(800) 716-4880

Quick Links

Recent News